The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 2, 2013, Pages 324-333

  Eba, Shunsuke ^a   Hoshikawa, Yasushi ^a   Moriguchi, Takashi ^b   Mitsuishi, Yoichiro ^b   Satoh, Hironori ^b   Ishida, Kazuyuki ^c   Watanabe, Tatsuaki ^a   Shimizu, Toru ^b   Shimokawa, Hiroaki ^b   Okada, Yoshinori ^a   Yamamoto, Masayuki ^b   Kondo, Takashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic hypoxia; Keap1; Nrf2; Pulmonary vascular remodeling; Reactive oxygen species

Indexed keywords

GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; OLTIPRAZ; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TENASCIN; TRANSCRIPTION FACTOR NRF2;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; GENE ACTIVATION; GENE SILENCING; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOBARISM; HYPOXIA; LUNG BLOOD VESSEL; MOUSE; MOUSE MUTANT; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; REGULATOR GENE; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANOXIA; ANTICARCINOGENIC AGENTS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRAZINES; TENASCIN;

EID: 84883168438     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0396OC     Document Type: Article

References (48)

1. Hultgren HN, Grover RF. Circulatory adaptation to high altitude. Annu Rev Med 1968;19: 119-152.
2. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol 1979;236:H818-H827.
3. Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am Rev Respir Dis 1984;130: 81-85.
4. Voelkel NF, Morris KG, McMurtry IF, Reeves JT. Calcium augments hypoxic vasoconstriction in lungs from high-altitude rats. J ApplPhysiol 1980;49: 450-455.
5. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129: 746-752.
6. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010;137:39S-51S.
7. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001;90: 1299-1306.
8. Matsui H, Shimosawa T, Itakura K, Guanqun X, Ando K, Fujita T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 2004;109: 2246-2251.
9. Lan AP, Xiao LC, Yang ZL, Yang CT, Wang XY, Chen PX, Gu MF, Feng JQ. Interaction between ROS and p38MAPK contributes to chemical hypoxia-induced injuries in PC12 cells. Mol Med Rep 2012;5: 250-255.
10. Lewis MS, Whatley RE, Cain P, McIntyre TM, Prescott SM, Zimmerman GA. Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest 1988;82: 2045-2055.
11. Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, Fang J, Jiang BH. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor- 1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006;41: 1521-1533.
12. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991;71: 2483-2492.
13. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195: 367-374.
14. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009;296:H1312-H1320.
15. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13: 1665-1678.
16. Itoh K, Wakabayashi N, Katoh Y, Ishii T, O'Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003;8: 379-391.
17. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. Oxidative stress sensor keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24: 7130-7139.
18. Taguchi K, Maher JM, Suzuki T, Kawatani Y, Motohashi H, Yamamoto M. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol Cell Biol 2010;30: 3016-3026.
19. Cowan KN, Jones PL, RabinovitchM. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-c antisense prevents progression, of vascular disease. J Clin Invest 2000;105: 21-34.
20. Hoshikawa Y, Nana-Sinkam P, Moore MD, Sotto-Santiago S, Phang T, Keith RL, Morris KG, Kondo T, Tuder RM, Voelkel NF, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics 2003;12: 209-219.
21. Cho HY, Reddy SP, Yamamoto M, Kleeberger SR. The transcription factor Nrf2 protects against pulmonary fibrosis. FASEB J 2004;18: 1258-1260.
22. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236: 313-322.
23. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, Geraci MW. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001;164: 314-318.
24. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, et al. The pulmonary circulation of homozygous or heterozygous NOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 1999;103: 291-299.
25. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174: 636-645.
26. Eba S, Hoshikawa Y, Mitsuishi Y, Sato H, Watanabe T, Watanabe Y, Maeda S, Okada Y, Kondo T. An Nrf2 activator, oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice [Abstract]. Am J Respir Crit Care Med 2011;183:A5487.
27. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169: 764-769.
28. Benson AB III. Oltipraz: a laboratory and clinical review. J Cell Biochem Suppl 1993;17F: 278-291.
29. Boone CW, Steele VE, Kelloff GJ. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 1992;267: 251-255.
30. Kensler TW, Egner PA,Dolan PM, Groopman JD, Roebuck BD.Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4- methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 1987;47: 4271-4277.
31. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of oh-bbn-induced bladder cancer in mice by oltipraz, alone and in combination with HPR and DFMO. Anticancer Res 1994;14: 5-11.
32. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficientmice. Proc Natl Acad Sci USA 2001;98: 3410-3415.
33. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther 2008;7: 3470-3479.
34. Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, Moore DD, Zhang Y, Klaassen CD, et al. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos 2008;36: 1716-1721.
35. Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, Jin T. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 2011;54: 922-934.
36. Rogers TK, Thompson JS, Morice AH. Inhibition of hypoxic pulmonary vasoconstriction in isolated rat resistance arteries by atrial natriuretic peptide. Eur Respir J 1997;10: 2061-2065.
37. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007;292:L885-L897.
38. Cho HY, Gladwell W, Wang X, Chorley B, Bell D, Reddy SP, Kleeberger SR. Nrf2-regulated PPARg expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med 2010;182: 170-182.
39. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Praticò D, Harrison DG, et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 2009;104:e42-e54.
40. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009;106: 250-255.
41. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, YamamotoM, Cui T. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009;29: 1843-1850.
42. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 2011;50: 940-950.
43. Block ER, Patel JM, Edwards D. Mechanism of hypoxic injury to pulmonary artery endothelial cell plasma membranes. Am J Physiol 1989;257:C223-C231.
44. Goven D, Boutten A, Leçon-Malas V, Marchal-Sommé J, Amara N, Crestani B, Fournier M, Lesèche G, Soler P, Boczkowski J, et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008;63: 916-924.
45. Cho HY, van Houten B, Wang X, Miller-Degraff L, Fostel J, Gladwell W, Perrow L, Panduri V, Kobzik L, Yamamoto M, et al. Targeted deletion of nrf2 impairs lung development and oxidant injury in neonatal mice. Antioxid Redox Signal 2012;17: 1066-1082.
46. Loboda A, Stachurska A, Florczyk U, Rudnicka D, Jazwa A,Wegrzyn J, Kozakowska M, Stalinska K, Poellinger L, Levonen AL, et al. HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. Antioxid Redox Signal 2009;11: 1501-1517.
47. Ueda K, Xu J, Morimoto H, Kawabe A, Imaoka S. MafG controls the hypoxic response of cells by accumulating HIF-1alpha in the nuclei. FEBS Lett 2008;582: 2357-2364.
48. Aziz SM, Toborek M, Hennig B, Mattson MP, Guo H, Lipke DW. Oxidative stress mediates monocrotaline-induced alterations in tenascin expression in pulmonary artery endothelial cells. Int J Biochem Cell Biol 1997;29: 775-787.